期刊
PLOS ONE
卷 10, 期 7, 页码 -出版社
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0133875
关键词
-
资金
- Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III [FIS PI030786]
- Centro de Investigacion Biomedica de Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM)
The composition and structure of the extracellular matrix (ECM) in the vascular wall and in the atherosclerotic plaque are important factors that determine plaque stability. Statins can stabilize atherosclerotic plaques by modulating ECM protein expression. Fibulins are important components of the ECM. We evaluated the in vitro effect of simvastatin on the expression of fibulin-1, -2, -4 and -5 in human coronary artery smooth muscle cells (SMCs) and the mechanisms involved. Cells were incubated with simvastatin (0.05-1 mu M), mevalonate (100 and 200 mu M), geranylgeranyl pyrophosphate (GGPP) (15 mu M), farnesyl pyrophosphate (FPP) (15 mu M), the Rho kinase (ROCK) inhibitor Y-27632 (15 and 20 mu M), the Rac-1 inhibitor (another member of Rho family) NSC23766 (100 mu M), arachidonic acid (a RhoA/ROCK activator, 25-100 mu M) and other fatty acids that are not activators of RhoA/ROCK (25100 mu M). Gene expression was analyzed by quantitative real-time PCR, and fibulin protein levels were analyzed by western blotting and ELISA. Simvastatin induced a significant increase in mRNA and protein levels of fibulin-2 at 24 hours of incubation (p<0.05), but it did not affect fibulin-1, -4, and -5 expression. Mevalonate and GGPP were able to reverse simvastatin's effect, while FPP did not. In addition, Y-27632, but not NSC23766, significantly increased fibulin-2 expression. Furthermore, activation of the RhoA/ROCK pathway with arachidonic acid decreased fibulin-2 mRNA. Simvastatin increased mRNA levels and protein expression of the ECM protein fibulin-2 through a RhoA and Rho-Kinase-mediated pathway. This increase could affect the composition and structure of the ECM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据